LR-90

• CAT Number: I019513
• CAS Number: 245075-84-7
• Molecular Formula: C₃₅H₃₄Cl₂N₄O₈
• Molecular Weight: 709.57
• Purity: ≥95%
• IUPAC Name: 2-[4-[[4-[[4-[[4-(2-carboxypropan-2-yloxy)phenyl]carbamoylamino]-3-chlorophenyl]methyl]-2-chlorophenyl]carbamoylamino]phenoxy]-2-methylpropanoic acid
• InChI: InChI=1S/C35H34Cl2N4O8/c1-34(2,30(42)43)48-24-11-7-22(8-12-24)38-32(46)40-28-15-5-20(18-26(28)36)17-21-6-16-29(27(37)19-21)41-33(47)39-23-9-13-25(14-10-23)49-35(3,4)31(44)45/h5-16,18-19H,17H2,1-4H3,(H,42,43)(H,44,45)(H2,38,40,46)(H2,39,41,47)
• InChIKey: WJDMCXSGUCNRPZ-UHFFFAOYSA-N
• SMILES: CC(C)(C(=O)O)OC1=CC=C(C=C1)NC(=O)NC2=C(C=C(C=C2)CC3=CC(=C(C=C3)NC(=O)NC4=CC=C(C=C4)OC(C)(C)C(=O)O)Cl)Cl

LR-90（Cat No.:I019513）is a small molecule compound that has been studied for its potential anticancer properties. It functions as a selective inhibitor of specific protein kinases involved in cell signaling pathways that regulate cell proliferation, survival, and metastasis. By targeting these kinases, LR-90 may help to disrupt the growth and spread of cancer cells. Research has also suggested its potential to enhance the effectiveness of other cancer treatments. Although preclinical studies have shown promising results, further investigation is required to assess LR-90’s safety, efficacy, and clinical applications in cancer therapy.

Reference

[1]. Figarola JL, et al. Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes. 2007 Mar;56(3):647-55.[2]. Figarola JL, et al. LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat. Diabetologia. 2008 May;51(5):882-91.